Complete Genomics (GNOM) reverses late session gains to trade lower in the post session after reporting a Q4 loss of $0.67 per share, compared with the prior-year period's $0.69 loss per share. Revenues were $2.5M, down 34% from $3.8M in the same quarter last year. The Street was expecting a loss of $0.65 on revenues of $3.15M. Shares -2.1% AH.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs